Introduction
============

Breast cancer is one of the most common cancers with an increasing mortality worldwide, while ovarian cancer is less frequent than breast cancer but is often fatal.[@b1-ott-10-227] Clinically, treatment of advanced breast cancer is often futile, and therefore, early diagnosis is critical to the therapy of breast cancer. In most cases, breast cancer occurs during the post-menopausal period, in which ovarian estrogen is no longer produced.[@b2-ott-10-227] It was reported that a number of novel genetic mutations were found in inherited breast and ovarian cancer patients.[@b3-ott-10-227] For example, mutations in *BRCA1* and *BRCA2* genes were often detected in the hereditary breast and ovarian cancer patients.[@b4-ott-10-227] Of hereditary breast and ovarian cancers, the familial hereditary variations accounted for only 10%.[@b5-ott-10-227] A previous study in American populations indicated that many molecular mutations were observed in both sporadic breast cancer and sporadic ovarian cancer.[@b1-ott-10-227] Six genetic techniques, including genomic DNA copy number arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing, and reverse-phase protein arrays, were used to detect gene mutations in this study. The data, concerning genetic variations of breast cancer and ovarian cancer, were calculated using statistical methods. Obviously, similar molecule mutations were found in both sporadic breast cancer and sporadic ovarian cancer. In addition, some other studies, focusing on rare genes such as *PALB2*, *ATM*, *CHEK2*, *BRIP1*, *RAD51C*, and *PPMID*, were performed, and these studies have also found few common genetic mutations.[@b6-ott-10-227] These risk modifiers could be applied to the early treatments of cancers, which is important for intensive screening and prophylactic surgery of cancer patients. The elucidation of risk allele is also helpful for clarifying the pathogenic mechanisms of cancers.

The gene, encoding methylenetetrahydrofolate reductase (*MTHFR*), is located at 1p36.3 and is highly polymorphic, in which the *C677T* polymorphic variant is most commonly studied and it can lead to Ala222Val.[@b7-ott-10-227] The *MTHFR C677T* polymorphism could reduce the production of MTHFR and affect enzyme activity.[@b8-ott-10-227] *MTHFR* is a crucial enzyme which has an important role in the regulation of methionine and homocysteine concentrations in folate metabolism.[@b9-ott-10-227] Folate is a necessity in intracellular metabolic processes such as DNA and RNA synthesis, DNA repair, and DNA methylation.[@b10-ott-10-227] Folate could regulate the transfer of one carbon unit in various biochemical reactions, which is complicated in various pathological processes such as breast cancer, ovarian cancer, colorectal cancer, gastric cancer, and lung cancer.[@b11-ott-10-227],[@b12-ott-10-227] Although many studies are conducted to investigate the association between *MTHFR C677T* polymorphism and breast and ovarian cancer, there is no conclusive evidence that *MTHFR C677T* is a common risk factor for breast cancer and ovarian cancer due to the influences of many factors such as ethnicity, source of control, and sample size.

Therefore, this study has performed this meta-analysis based on published eligible case--control studies to evaluate the role of *MTHFR C677T* polymorphism in breast cancer and/or ovarian cancer risk.

Materials and methods
=====================

Publication search
------------------

PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), WanFang, and Database of Chinese Scientific and Technical Periodicals (VIP) were searched to identify the articles that investigate the association of *MTHFR C677T* polymorphism with breast and ovarian cancer risk. The retrieval was performed using the keywords: "breast neoplasms," "breast cancer," "breast carcinoma," "ovarian carcinoma," "ovarian neoplasms," "ovarian cancer," "*MTHFR*," "Methylenetetrahydrofolate Reductase (*NADPH2*)," "*C677T*," "rs1801133," and the latest search was updated until June 2016. In addition, articles published only in English and Chinese were identified, while the full-text of the retrieved articles was scrutinized to confirm that these data were required for this study.

Inclusion and exclusion criteria
--------------------------------

Studies were included if they met the following inclusion criteria: 1) case--control studies, 2) investigating the association of *MTHFR C677T* polymorphism with breast and ovarian cancer risk, 3) genotype data of cases and controls were complete, and 4) genotype distribution of control must comply with the Hardy--Weinberg equilibrium (HWE). The exclusion criteria were as follows: 1) duplicated studies, 2) no detailed information of genotype data, and 3) meta-analysis and reviews.

Data extraction
---------------

Two authors assessed the quality of the included studies independently and extracted the following information: the name of first author, year of publication, country of origin, ethnicity, sample size, and genotype data. In case of conflicting information, divergence was resolved through discussion with the team. The population was divided into the Asians and Caucasians.

Quality score assessment
------------------------

The quality of the included studies was assessed with the Newcastle--Ottawa scale (NOS) (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>) table. Two authors calculated the score of each study, respectively. The maximum score was 9, and a score ≥7 denoted that the study was of high quality.

Statistical analysis
--------------------

HWE of the included studies was assessed with *χ*^2^ test. The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the association between *MTHFR C677T* and breast and ovarian cancer risk.[@b13-ott-10-227] Allele model, co-dominant model, dominant model, recessive model, and homozygous model were utilized to assess the association of the *MTHFR C677T* polymorphism with the risk of breast cancer and/or ovarian cancer. Moreover, a subgroup analysis based on ethnicity and source of control were conducted to reduce the heterogeneity. The chi-square-based *Q* test (*P*\<0.05, the significant level of statistical heterogeneity) and *I*^2^ index (*I*^2^≥50%, the significant level of statistical heterogeneity) were used to evaluate the inconsistencies among studies, and the two values were shown on the forest plots.[@b14-ott-10-227],[@b15-ott-10-227] The fixed effect model, deriving from the Mantel-Haenszel method, was applied when heterogeneity did not exist, and the random effect model, depending on the DerSimonian and Laird method, was carried out in case of significant heterogeneity.[@b16-ott-10-227],[@b17-ott-10-227] Egger's test and Begg's test were conducted to examine the publication bias.[@b18-ott-10-227] Sensitivity analysis was performed by removing each study and was applied to observe stabilization of the results. All statistical analyses were conducted using Stata (version 12.0; StataCorp LP, College Station, TX, USA) software. In addition, the *P*-value is two sided, and *P*\<0.05 was considered statistically significant.

Results
=======

Literature selection
--------------------

A total of 137 articles with 6 reviews and 22 meta-analyses were retrieved in initial search from PubMed, Embase, Web of Science, CNKI, WanFang, and VIP databases. About 28 articles were excluded as they were not case--control studies; 70 articles were included after analyzing the titles and abstracts; and 8 articles were excluded after reading the full-text. HWE was carried out to analyze the genetic equilibrium of the included studies, and 12 studies were excluded (*P*\<0.05).[@b19-ott-10-227]--[@b26-ott-10-227] Finally, 50 publications, involving 19,260 cases and 26,364 controls, were selected in this meta-analysis. The information of first author, ethnicity, nationality, cancer type, genotyping method, source of control, and genotype frequency was extracted ([Table 1](#t1-ott-10-227){ref-type="table"}, [Figure 1](#f1-ott-10-227){ref-type="fig"}).

Quantitative analysis
---------------------

In the overall and subgroup analysis, five genetic models were applied to evaluate the association of *MHTFR C677T* polymorphism with the risk of breast cancer and/or ovarian cancer. The results indicated that there was a significant correlation between *MTHFR C677T* polymorphism and breast cancer risk: allele model C vs T, OR =1.19, CI: 1.12--1.28, *P*\<0.05; homozygous model CC vs TT, OR =1.20, CI: 1.12--1.28, *P*\<0.05; recessive model (CT+CC) vs TT, OR =1.19, CI: 1.11--1.27, *P*\<0.05; dominant model CC vs (CT+TT), OR =1.19, CI: 1.79--1.95, *P*\<0.05. However, no significantly increased ovarian cancer risk was found (allele model C vs T, OR =1.03, CI: 0.98--1.09, *P*=0.26; homozygous model CC vs TT, OR =1.05, CI: 0.93--1.18, *P*=0.45; recessive model TT vs (CT+CC), OR =1.02, CI: 0.92--1.15, *P*=0.68; dominant model CC vs (CT+TT), OR =1.05, CI: 0.97--1.13, *P*=0.21; co-dominant model TT vs CT, OR =1.05, CI: 0.97--1.29, *P*=0.24). In the subgroup analysis by ethnicity, the results reflected that the *MTHFR C677T* mutation could significantly increase the breast cancer risk in both Caucasians and Asians ([Table 2](#t2-ott-10-227){ref-type="table"}). None of the genetic models indicated a significant association between *MTHFR C677T* polymorphism and ovarian cancer risk in Caucasians, while significant ovarian cancer risk was observed in Asians: allele model C vs T, OR =1.19, CI: 1.13--1.25, *P*\<0.05; homozygous model CC vs TT, OR =1.43, CI: 1.30--1.59, *P*\<0.05; recessive model TT vs (CT+CC), OR =1.35, CI: 1.23--1.48, *P*\<0.05; dominant model CC vs (CT+TT), OR =1.20, CI: 1.12--1.28, *P*\<0.05; co-dominant model TT vs CT, OR =1.13, CI: 1.05--1.21, *P*\<0.05 ([Table 3](#t3-ott-10-227){ref-type="table"}). In addition, forest plots have been drawn to observe the weight of each included study and estimate the association of *MTHFR C677T* polymorphism with the relative risk of breast cancer and/or ovarian cancer using the homozygous genetic model (CC vs TT). In the meantime, the stratified analyses based on ethnicity, cancer type, and control type were conducted to eliminate the heterogeneity among studies ([Figures 2](#f2-ott-10-227){ref-type="fig"} and [3](#f3-ott-10-227){ref-type="fig"}).

Sensitivity analysis and publication bias
-----------------------------------------

Sensitivity analysis indicated that the results were stable, and the summary ORs were not materially altered by excluding individual data set at each time. Moreover, no significant publication bias was shown according to Begg's test and Egger's test ([Figures 4](#f4-ott-10-227){ref-type="fig"}[](#f5-ott-10-227){ref-type="fig"}--[6](#f6-ott-10-227){ref-type="fig"}).

Discussion
==========

In previous studies, strong evidences show that genetic variations, involving DNA metabolism, existed in breast cancer and/or ovarian cancer.[@b27-ott-10-227],[@b28-ott-10-227] Because of the central roles of these genes in cell metabolism, the changes in the functions of these genes may increase the risk of cancers. As is well known, *MTHFR C677T* polymorphism could alter *MTHFR* enzyme activity, which affected the general balance in the process of DNA repair, DNA methylation, and DNA synthesis.[@b29-ott-10-227] Therefore, *MTHFR* might have a potential effect on the origin and progress of breast cancer and ovarian cancer.[@b30-ott-10-227] Several studies have been conducted to evaluate the contribution of *MTHFR C677T* polymorphism to breast and ovarian cancer, but the sample size, ethnicity, and the source of control were limited.[@b31-ott-10-227],[@b32-ott-10-227] In the study of Lu et al, the results suggested that *MTHFR C677T* polymorphism might be significantly associated with the risk and prognosis of breast cancer in Chinese population.[@b33-ott-10-227] Although the age has been corrected and the genotype data of control comply with the law of HWE in this study, the conclusion was still indeterminable because of small sample size and the influence of other environmental factors. The same results were also observed in other studies.[@b34-ott-10-227]--[@b36-ott-10-227] In addition, there was a common problem in the studied Chinese populations, that is, the population of control often came from the hospital. This might reduce the persuasion of research results. Hence, in the meta-analysis, the subgroup analysis based on the source of control was conducted to increase the power of statistics and achieve a more accurate result. On the other hand, significant association between *MTHFR C677T* and breast cancer risk was also detected in Caucasians.[@b37-ott-10-227],[@b38-ott-10-227] However, contrasting results were described in Asians and Caucasians for breast cancer risk.[@b39-ott-10-227]--[@b43-ott-10-227] In the studies for ovarian cancer, Gao et al found that the *MTHFR C677T* polymorphism was significantly associated with the susceptibility and the survival of ovarian cancer.[@b31-ott-10-227],[@b45-ott-10-227],[@b46-ott-10-227] Nevertheless, other results indicated that no association of *MTHFR C677T* polymorphism with ovarian cancer risk existed.[@b47-ott-10-227],[@b48-ott-10-227] The different results from these studies showed that the correlation between *MTHFR C677T* polymorphism and breast cancer and/or ovarian cancer risk were still inconclusive. Hence, the pooled analysis was carried out to analyze the correlation of *MTHFR C677T* polymorphism with breast cancer and/or ovarian cancer risk.

In the overall analysis, the results suggested that the *MTHFR C677T* polymorphism might significantly increase the breast cancer risk but not ovarian cancer risk. The CC genotype carriers had a higher breast cancer risk than that of TT genotype carriers in Asians. In the analysis of total population, the *P*-value and ORs revealed that breast cancer and/or ovarian cancer risk were significantly associated with *MTHFR C677T* polymorphism. Furthermore, the cumulative results indicated that TT allele carrier had a higher risk of breast cancer and/or ovarian cancer than the CC allele carrier. From the subgroup analysis, more significant risk of breast cancer and/or ovarian cancer was detected in Asians (for CC vs TT, *P*\<0.05, OR =1.19, CI: 1.13--1.25).

According to subgroup analysis, source of control and ethnicity might have a great effect on the results. The results showed that the hospital-based case--control studies mainly contributed to the heterogeneity among ovarian cancer research studies. Based on the included studies for breast cancer, it could be mentioned that the main cause of heterogeneity might be ethnicity. In the stratified meta-analysis based on ethnicity for breast cancer, compared with C allele, a significantly increased breast cancer risk was significantly associated with T allele in Asians (C vs T, *P*\<0.05, OR =1.12, CI: 1.06--1.18; CC vs TT, *P*\<0.05, OR =1.29, CI: 1.16--1.44; CC vs (CT+TT), *P*\<0.05, OR =1.10, CI: 1.03--1.18; (CC+CT) vs TT, *P*\<0.05, OR =1.27, CI: 1.15--1.40). Under C vs T allele model, the polymorphism of *MTHFR C677T* could increase the risk of ovarian cancer in Asians (C vs T, *P*\<0.05, OR =1.52, CI: 1.29--1.80). No statistical significance was detected between *MTHFR C677T* polymorphism and ovarian cancer risk in Caucasians. The T allele significantly increased ovarian cancer risk in the studies of hospital-based control (CC vs (CT+TT), *P*\<0.05, OR =1.18, CI: 1.07--1.31). Subgroup analysis based on cancer type in Asians revealed that *MTHFR C677T* mutation could significantly increase the risk of ovarian cancer (allele model C vs T, OR =1.52, CI: 1.29--1.80, *P*\<0.05; homozygous model CC vs TT, OR =2.74, CI: 1.85--4.06, *P*\<0.05; recessive model TT vs (CT+CC), OR =2.46, CI: 1.68--3.59, *P*\<0.05; dominant model CC vs (CT+TT), OR =1.49, CI: 1.21--1.84, *P*\<0.05; co-dominant model TT vs CT, OR =1.30, CI: 1.04--1.63, *P*\<0.05). The allele T carriers might have a higher breast cancer and/or ovarian cancer risk in Asians, which might result from the influence of the *MTHFR* enzyme in tumor cells.[@b9-ott-10-227]

Several factors such as selection criteria of cases, age distribution, sample size, family history, ethnicity, source of control, and lifestyle might lead to the heterogeneity among studies. There was no significant publication bias based on Begg's test and Egger's test. In addition, no significant changing of the results was found in sensitivity analysis, which demonstrated the results were stable in the meta-analysis. And the studies that were not consistent with the HWE in the meta-analysis were excluded in order to improve the accuracy of the results.

According to the results, it was clear that the *MTHFR C677T* variant could increase the breast cancer and/or ovarian cancer risk in Asians. These results provided obvious evidence that metabolism genes could increase the risk of breast and ovarian cancer. Most notably, because of some genetic differences in Asians and Caucasians, the *MTHFR C677T* polymorphism might have a different effect on breast cancer and/or ovarian cancer in the two populations. But given the different role of gene variations in cell differentiation and proliferation, the function experiment and clinic trial were still needed to confirm the conclusions of this meta-analysis.[@b49-ott-10-227] Furthermore, environmental factors might have an important influence in breast cancer and/or ovarian cancer risk. Hence, it was expected that studies including environmental factors were carried out.

In summary, this meta-analysis demonstrated that the *MTHFR C677T* mutation might increase the risk of both breast cancer and ovarian cancer, especially in Asians. It provided a new insight into the molecular origin of breast cancer and ovarian cancer. Considering the limitations of the study, large well-designed studies including different ethnic populations should be conducted to further assess the association of the *MTHFR C677T* polymorphisms with increased susceptibility to breast cancer and/or ovarian cancer.
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###### 

Characteristics of the studies included in this meta-analysis

  First author                           Year   Nationality   Ethnicity    Cancer type   Patient/control   Control   Patient   *P* for HWE   Score   Control type                    
  -------------------------------------- ------ ------------- ------------ ------------- ----------------- --------- --------- ------------- ------- -------------- ----- ------ --- ------------
  Sharp[@b50-ott-10-227]                 2002   England       Caucasians   BC            54/57             25        21        11            30      19             5     0.10   7   PB
  Campbell[@b38-ott-10-227]              2002   England       Caucasians   BC            335/233           118       92        23            140     162            33    0.42   8   HB
  Ergul[@b51-ott-10-227]                 2003   Turkey        Mixed        BC            118/193           94        87        12            60      41             17    0.16   7   HB
  Semenza[@b41-ott-10-227]               2003   USA           Caucasians   BC            105/247           112       111       24            42      58             5     0.64   7   HB
  Langsenlehner[@b37-ott-10-227]         2003   Austrian      Caucasians   BC            494/495           215       215       65            208     222            64    0.33   8   PB
  Grieu[@b39-ott-10-227]                 2004   Australia     Caucasians   BC            307/551           242       259       50            166     141            27    0.10   8   PB
  Forsti[@b40-ott-10-227]                2004   Finland       Caucasians   BC            223/298           181       104       13            134     81             8     0.69   7   Not stated
  Lee[@b52-ott-10-227]                   2004   Korea         Asians       BC            186/147           50        80        17            58      96             32    0.08   7   HB
  Qi[@b34-ott-10-227]                    2004   China         Asians       BC            217/218           59        105       54            42      104            71    0.59   7   HB
  Lin[@b53-ott-10-227]                   2004   China         Asians       BC            88/342            173       145       24            43      38             7     0.39   8   PB
  Shrubsole[@b54-ott-10-227]             2004   China         Asians       BC            1,112/1,160       387       577       196           374     555            183   0.44   8   PB
  Justenhoven[@b55-ott-10-227]           2005   Germany       Caucasians   BC            584/633           261       279       93            249     274            61    0.19   8   PB
  Kalemi[@b56-ott-10-227]                2005   Greece        Caucasians   BC            42/51             23        20        8             19      16             7     0.31   7   Not stated
  Deligezer[@b57-ott-10-227]             2005   Turkey        Mixed        BC            189/223           128       83        12            98      68             23    0.76   7   Not stated
  Chou[@b58-ott-10-227]                  2006   China         Asians       BC            142/285           132       120       33            73      51             18    0.47   7   HB
  Reljic[@b59-ott-10-227]                2007   Croatia       Caucasians   BC            93/65             27        34        4             40      44             9     0.11   7   PB
  Hekim[@b60-ott-10-227]                 2007   Turkey        Mixed        BC            40/68             38        26        4             22      16             2     0.87   7   Not stated
  Xu[@b61-ott-10-227]                    2007   USA           Mixed        BC            1,063/1,104       440       509       155           398     476            189   0.69   7   PB
  Macis[@b62-ott-10-227]                 2007   Italy         Caucasians   BC            46/80             28        41        11            14      20             12    0.51   7   PB
  Yu[@b63-ott-10-227]                    2007   China         Asians       BC            119/420           225       170       25            56      54             9     0.34   7   PB
  Kotsopoulos[@b64-ott-10-227]           2008   Canada        Caucasians   BC            944/680           252       341       87            383     421            140   0.09   7   HB
  Langsenlehner[@b65-ott-10-227]         2008   Austrian      Caucasians   BC            105/105           40        48        17            51      43             11    0.68   7   Not stated
  Cheng[@b66-ott-10-227]                 2008   China         Asians       BC            349/530           268       221       41            185     133            31    0.62   7   HB
  Inoue[@b67-ott-10-227]                 2008   Singapore     Asians       BC            380/662           393       226       43            239     120            21    0.18   8   PB
  Suzuki[@b68-ott-10-227]                2008   Japan         Asians       BC            454/909           338       425       146           150     220            84    0.52   7   HB
  Cam[@b69-ott-10-227]                   2009   Turkey        Mixed        BC            110/95            47        42        6             48      49             13    0.4    7   Not stated
  Henriquez-Hernandez[@b70-ott-10-227]   2009   Spain         Caucasians   BC            135/292           107       138       47            52      65             18    0.82   7   PB
  Platek[@b71-ott-10-227]                2009   USA           Caucasians   BC            994/1,802         788       795       219           429     446            119   0.40   7   PB
  Ericson[@b72-ott-10-227]               2009   Sweden        Caucasians   BC            540/1,074         531       452       91            255     235            50    0.71   8   PB
  Maruti[@b73-ott-10-227]                2009   USA           Mixed        BC            318/647           301       284       62            133     139            46    0.67   7   PB
  Ma[@b74-ott-10-227]                    2009   Brazil        Mixed        BC            458/458           222       187       49            225     188            45    0.31   7   HB
  Li[@b42-ott-10-227]                    2009   China         Asians       BC            65/143            90        50        3             38      17             10    0.19   7   PB
  Jin[@b43-ott-10-227]                   2009   China         Asians       BC            41/100            49        41        10            18      20             3     0.74   7   Not stated
  Yuan[@b35-ott-10-227]                  2009   China         Asians       BC            80/80             32        35        13            16      35             29    0.52   7   HB
  Gao[@b36-ott-10-227]                   2009   China         Asians       BC            624/624           235       301       88            202     305            117   0.59   7   PB
  Ma[@b75-ott-10-227]                    2009   Japan         Asians       BC            388/387           115       188       84            124     183            81    0.66   7   HB
  Bentley[@b76-ott-10-227]               2010   USA           Caucasians   BC            939/1,226         429       592       205           346     402            191   0.97   7   HB
  Prasad[@b47-ott-10-227]                2011   India         Asians       BC            130/125           116       8         1             124     5              1     0.06   7   Not stated
  Wu[@b77-ott-10-227]                    2012   China         Asians       BC            75/75             37        32        6             32      30             13    0.80   7   HB
  Akilzhanova[@b78-ott-10-227]           2013   Kazakhstan    Asians       BC            315/604           287       269       48            181     109            25    0.17   7   HB
  Lu[@b33-ott-10-227]                    2015   China         Asians       BC            560/560           226       250       84            170     288            102   0.28   8   HB
  Pooja[@b44-ott-10-227]                 2015   India         Asians       BC            588/508           386       111       11            437     134            17    0.37   8   HB
  Awwad[@b79-ott-10-227]                 2015   Jordan        Caucasians   BC            150/146           79        51        16            66      69             15    0.09   7   HB
  Wu[@b46-ott-10-227]                    2007   China         Asians       OC            81/80             32        35        13            17      40             24    0.52   7   HB
  Terry1[@b48-ott-10-227]                2010   USA           Caucasians   OC            1,059/1,125       499       488       138           427     492            140   0.27   7   HB
  Terry2[@b48-ott-10-227]                2010   USA           Caucasians   OC            158/496           210       217       55            71      72             10    0.93   7   HB
  Terry3[@b48-ott-10-227]                2010   USA           Caucasians   OC            364/412           193       168       51            164     167            33    0.13   7   HB
  Webb[@b80-ott-10-227]                  2011   Australian    Mixed        OC            1,638/1,278       571       568       139           744     709            185   0.90   7   PB
  Prasad[@b47-ott-10-227]                2011   India         Asians       OC            80/125            116       8         1             72      3              5     0.06   7   Not stated
  Pawlik[@b81-ott-10-227]                2011   Poland        Caucasians   OC            136/160           63        79        18            67      55             13    0.36   7   PB
  Jakubowska[@b31-ott-10-227]            2012   Poland        Caucasians   OC            985/3,350         1,447     1,481     422           423     446            116   0.16   8   HB
  Zhang[@b82-ott-10-227]                 2012   China         Asians       OC            215/218           115       92        11            102     94             19    0.17   7   HB
  Gao[@b45-ott-10-227]                   2012   China         Asians       OC            224/432           232       178       22            97      100            27    0.10   7   HB

**Abbreviations:** HWE, Hardy--Weinberg equilibrium; OC, ovarian cancer; BC, breast cancer; HB, hospital-based control; PB, population-based control; Mixed, mixed population.

###### 

Results of meta-analysis for the association of *MTHFR C677T* polymorphism with breast cancer and/or ovarian cancer risk (ethnicity and source of control)

  *MTHFR C677T*   C vs T              CC vs TT   CC vs (CT+TT)       (CC+CT) vs TT   CC vs CT            Heterogeneity                                                                     
  --------------- ------------------- ---------- ------------------- --------------- ------------------- --------------- ------------------- -------- ------------------- -------- ------- -------
  Total           1.07 (1.04--1.10)   \<0.05     1.16 (1.10--1.23)   \<0.05          1.06 (1.02--1.10)   0.003           1.15 (1.08--1.21)   \<0.05   1.13 (1.06--1.20)   \<0.05   51.4    0.000
  BC              1.19 (1.12--1.28)   \<0.05     1.20 (1.12--1.28)   \<0.05          1.19 (1.79--1.95)   \<0.05          1.19 (1.11--1.27)   \<0.05   1.02 (0.98--1.07)   0.34     44.2    0.001
  OC              1.03 (0.98--1.09)   0.26       1.05 (0.93--1.18)   0.45            1.05 (0.97--1.13)   0.21            1.02 (0.92--1.15)   0.68     1.05 (0.97--1.13)   0.24     71.1    0.000
  Asians          1.19 (1.13--1.25)   \<0.05     1.43 (1.30--1.59)   \<0.05          1.20 (1.12--1.28)   \<0.05          1.35 (1.23--1.48)   \<0.05   1.13 (1.05--1.21)   \<0.05   57.8    0.000
  Caucasians      1.01 (0.97--1.05)   0.61       1.01 (0.93--1.18)   0.77            1.02 (0.96--1.07)   0.53            1.00 (0.93--1.09)   0.93     1.02 (0.96--1.08)   0.52     10.2    0.324
  HB              1.15 (1.10--1.21)   \<0.05     1.37 (1.24--1.52)   \<0.05          1.13 (1.06--1.21)   \<0.05          1.33 (1.20--1.46)   \<0.05   1.07 (1.00--1.15)   \<0.05   56.3    0.000
  PB              1.07 (1.03--1.11)   \<0.05     1.16 (1.06--1.27)   \<0.05          1.07 (1.01--1.13)   \<0.05          1.14 (1.05--1.24)   \<0.05   1.04 (0.98--1.11)   0.15     52.20   0.004

**Abbreviations:** MTHFR, methylenetetrahydrofolate reductase; OC, ovarian cancer; BC, breast cancer; HB, hospital-based control; PB, population-based control; OR, odds ratio; CI, confidence interval.

###### 

Results of subgroup analysis based on ethnicity and source of control

  *MTHFR C677T*   Cancer type   C vs T              CC vs TT   CC vs (CT+TT)       (CC+CT) vs TT   CC vs CT                                                                      
  --------------- ------------- ------------------- ---------- ------------------- --------------- ------------------- -------- ------------------- -------- ------------------- --------
  Caucasians      BC            1.01 (0.96--1.06)   0.62       1.04 (0.93--1.16)   0.50            1.01 (0.94--1.08)   0.87     1.04 (0.94--1.15)   0.45     1.00 (0.93--1.07)   0.93
                  OC            1.00 (0.94--1.07)   0.95       0.96 (0.82--1.11)   0.55            1.04 (0.95--1.14)   0.44     0.93 (0.80--1.07)   0.30     1.06 (0.96--1.17)   0.24
  Asians          BC            1.12 (1.06--1.18)   \<0.05     1.29 (1.16--1.44)   \<0.05          1.10 (1.03--1.18)   \<0.05   1.27 (1.15--1.40)   \<0.05   1.05 (0.97--1.12)   0.23
                  OC            1.52 (1.29--1.80)   \<0.05     2.74 (1.85--4.06)   \<0.05          1.49 (1.21--1.84)   \<0.05   2.46 (1.68--3.59)   \<0.05   1.30 (1.04--1.63)   \<0.05
  HB              BC            1.06 (1.01--1.11)   \<0.05     1.18 (1.07--1.31)   \<0.05          1.02 (0.96--1.10)   0.48     1.19 (1.08--1.31)   \<0.05   0.98 (0.91--1.05)   0.57
                  OC            1.06 (1.00--1.14)   0.06       1.09 (0.94--1.25)   0.25            1.11 (1.01--1.21)   \<0.05   1.03 (0.90--1.18)   0.67     1.11 (1.02--1.22)   \<0.05
  PB              BC            1.10 (1.05--1.15)   \<0.05     1.22 (1.11--1.34)   \<0.05          1.11 (1.04--1.18)   \<0.05   1.17 (1.07--1.29)   \<0.05   1.08 (1.01--1.15)   \<0.05
                  OC            0.97 (0.87--1.08)   0.55       0.99 (0.78--1.25)   0.91            0.94 (0.81--1.08)   0.35     1.03 (0.82--1.28)   0.82     0.92 (0.80--1.07)   0.29

**Abbreviations:** MTHFR, methylenetetrahydrofolate reductase; OC, ovarian cancer; BC, breast cancer; HB, hospital-based control; PB, population-based control; OR, odds ratio; CI, confidence interval.
